New Blood Test Could Spot Lung Cancer Years Sooner

In June 2026, a study published in Cell suggested that a set of blood proteins could predict lung cancer five years before symptoms appear. Researchers from institutions including The Francis Crick Institute and University College London identified these markers using machine-learning techniques on data from the U.K. Biobank. The findings indicated that this 14-protein signature reflects a 'perturbed lung environment' and is associated with an increased risk of lung cancer, as well as other chronic lung diseases like COPD.

Additionally, the research explored the potential of Canakinumab, a monoclonal antibody targeting interleukin-1 beta, to reduce lung cancer risk. This hypothesis stems from a retrospective analysis of the CANTOS trial, which initially investigated cardiovascular outcomes. While the drug showed a reduction in lung cancer cases in that trial, it's important to note this was an unexpected finding and not the trial's primary objective.

Interpreting these results requires caution. The identified protein markers may indicate general lung unhealthiness due to factors like smoking or pollution, rather than being direct cancer detectors. The purported preventive effect of Canakinumab also lacks independent replication and is overshadowed by the drug's known risk of fatal infections. Medical research complexity necessitates careful analysis, independent validation, and avoiding overly optimistic conclusions from single studies.